BRPI0506791A - método para imitar uma resposta à insulina de primeira fase refeição-relacionada fisiológica em diabetes do tipo 2 - Google Patents

método para imitar uma resposta à insulina de primeira fase refeição-relacionada fisiológica em diabetes do tipo 2

Info

Publication number
BRPI0506791A
BRPI0506791A BRPI0506791-0A BRPI0506791A BRPI0506791A BR PI0506791 A BRPI0506791 A BR PI0506791A BR PI0506791 A BRPI0506791 A BR PI0506791A BR PI0506791 A BRPI0506791 A BR PI0506791A
Authority
BR
Brazil
Prior art keywords
insulin
administration
levels
type
diabetes
Prior art date
Application number
BRPI0506791-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Wayman Wendell Cheatham
Andreas Pfuetzner
Andrers Hasager Boss
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of BRPI0506791A publication Critical patent/BRPI0506791A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0506791-0A 2004-01-12 2005-01-10 método para imitar uma resposta à insulina de primeira fase refeição-relacionada fisiológica em diabetes do tipo 2 BRPI0506791A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53594504P 2004-01-12 2004-01-12
PCT/US2005/000596 WO2005067964A1 (en) 2004-01-12 2005-01-10 A method of reducing serum proinsulin levels in type 2 diabetics

Publications (1)

Publication Number Publication Date
BRPI0506791A true BRPI0506791A (pt) 2007-05-22

Family

ID=34794375

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506791-0A BRPI0506791A (pt) 2004-01-12 2005-01-10 método para imitar uma resposta à insulina de primeira fase refeição-relacionada fisiológica em diabetes do tipo 2

Country Status (11)

Country Link
US (1) US20050153874A1 (enExample)
EP (1) EP1708738B1 (enExample)
JP (1) JP2007517892A (enExample)
KR (2) KR20060110353A (enExample)
CN (1) CN101027082A (enExample)
AU (2) AU2005204378B2 (enExample)
BR (1) BRPI0506791A (enExample)
ES (1) ES2584867T3 (enExample)
IL (1) IL176699A (enExample)
NZ (1) NZ548980A (enExample)
WO (1) WO2005067964A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
EP2280004B1 (en) 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20070027063A1 (en) * 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
PL2319500T3 (pl) * 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
AU2006213084A1 (en) * 2005-01-10 2006-08-17 Mannkind Corporation Methods and compositions for minimizing accrual of inhalable insulin in the lungs
ES2439455T3 (es) * 2005-08-01 2014-01-23 Mannkind Corporation Procedimiento de preservar la función de las células productoras de insulina
KR101384456B1 (ko) * 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
AU2009204309B2 (en) * 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US11110151B2 (en) * 2008-08-11 2021-09-07 Mannkind Corporation Composition and method for reducing hypoglycemia events in diabetes treatment
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
SI2379100T1 (sl) * 2009-01-08 2015-02-27 Mannkind Corporation Zdravljenje hiperglikemije z GLP-1
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
CA3098386C (en) 2012-07-12 2022-11-29 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
MX369136B (es) 2013-03-15 2019-10-30 Mannkind Corp Composiciones de dicetopiperazina microcristalina y metodos.
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN110187123B (zh) * 2019-05-06 2022-07-22 天津医科大学总医院 一种糖尿病早期诊断生物标志物及其应用
CN111235036B (zh) * 2020-01-15 2022-03-18 西北大学 一种冠突散囊菌及从其中分离纯化二酮哌嗪二聚体的方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (enExample) * 1973-04-04 1978-04-14 Isf Spa
GB1479283A (en) * 1973-07-23 1977-07-13 Bespak Industries Ltd Inhaler for powdered medicament
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
ATE76311T1 (de) * 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
US5492112A (en) * 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
ES2141108T3 (es) * 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
JP3121080B2 (ja) * 1991-12-19 2000-12-25 アール・ピー・シーラー コーポレイション カプセル封入用溶液
CA2127877A1 (en) * 1992-01-21 1993-07-22 Robert M. Platz Improved process for preparing micronized polypeptide drugs
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
UA27938C2 (uk) * 1992-10-19 2000-10-16 Д'Юра Фармас'Ютікалз, Інк Пристрій для розпилення лікарського засобу у формі порошку для інгаляції
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5364838A (en) * 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
WO1995013796A1 (en) * 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
JPH10501519A (ja) * 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
CN1170409A (zh) * 1994-12-01 1998-01-14 富山化学工业株式会社 新的2,3－二氧代哌嗪衍生物及其盐
US5901703A (en) * 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5807315A (en) * 1995-11-13 1998-09-15 Minimed, Inc. Methods and devices for the delivery of monomeric proteins
DE19545257A1 (de) * 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE321536T1 (de) 1999-04-05 2006-04-15 Mannkind Corp Verfahren zur bildung von feinem pulver
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP2280004B1 (en) 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US6294317B1 (en) * 1999-07-14 2001-09-25 Xerox Corporation Patterned photoresist structures having features with high aspect ratios and method of forming such structures
US7464706B2 (en) * 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
EP1666028B1 (en) * 1999-10-29 2010-03-24 Novartis AG Dry powder compositions having improved dispersivity
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US20030096403A1 (en) * 2000-10-02 2003-05-22 Hyo-Jeong Hong Humanized antibody to surface antigen s of hepatitis b virus and a preparing method thereof
US20020138369A1 (en) 2001-03-22 2002-09-26 Calaway Douglas D. Electronic storage medium and purchasing system and method
EP1438019A1 (en) * 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Kit for the preparation of a pharmaceutical composition
US20030194420A1 (en) * 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
AU2003286796A1 (en) * 2002-10-31 2004-06-07 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
JP2006514119A (ja) * 2003-02-12 2006-04-27 アール アンド ピー コリア カンパニー リミテッド 溶解率が向上した難溶性薬剤の溶媒系
PL2319500T3 (pl) * 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations

Also Published As

Publication number Publication date
KR20060110353A (ko) 2006-10-24
AU2009200894B2 (en) 2010-11-18
JP2007517892A (ja) 2007-07-05
CA2552707C (en) 2018-03-27
AU2009200894A1 (en) 2009-03-26
ES2584867T3 (es) 2016-09-29
NZ548980A (en) 2009-10-30
WO2005067964A1 (en) 2005-07-28
EP1708738B1 (en) 2016-05-04
CA2552707A1 (en) 2005-07-28
IL176699A (en) 2011-11-30
AU2005204378B2 (en) 2009-01-22
KR20090096756A (ko) 2009-09-14
US20050153874A1 (en) 2005-07-14
KR100985126B1 (ko) 2010-10-05
CN101027082A (zh) 2007-08-29
AU2005204378A1 (en) 2005-07-28
EP1708738A1 (en) 2006-10-11
IL176699A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
BRPI0506791A (pt) método para imitar uma resposta à insulina de primeira fase refeição-relacionada fisiológica em diabetes do tipo 2
Ahrén et al. Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans
Aryangat et al. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk
Vilsbøll et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Holst et al. Combining GLP‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
BRPI0406499A (pt) Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
Rodbard et al. Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomized, 18‐week, open‐label, phase 3 trial (onset 3)
Davies et al. Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial
EA200900626A1 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
BR0318046A (pt) Compostos de hidroxila e composições para controle de colesterol e empregos relacionados
BRPI0516126A (pt) produtos farmacêuticos de polipeptìdeos intestinais vasoativos
DK2027870T3 (da) Kontrol af blodglucose ved diabetesbehandling under anvendelse af pulmonært indgivet insulin i kombination med basalinsulin
BR0314799A (pt) Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
BR112021016782A2 (pt) Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica
Yki‐Järvinen Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus
Ginsberg et al. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
NO20070174L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi
Unger Insulin initiation and intensification in patients with T2DM for the primary care physician
BR112019000991A2 (pt) análogo da insulina, composição farmacêutica, método para tratar e/ou prevenir uma afeção relacionada com insulina, método para decrescer níveis de glicose no sangue, uso do análogo da insulina, método de replanejamento ou modificação de um polipeptídeo que é conhecido por se ligar a um receptor da insulina, polipeptídeo, molécula isolada, método para identificar um composto que se liga ao receptor de insulina, método de base computacional para identificar um composto que imita a atividade da insulina, composto identificado usando um método, cristal do polipeptídeo, estrutura do polipeptídeo, uso da estrutura, uso do modelo estrutural, peptídeo, método para aumentar a ativação do receptor da insulina em um sujeito, método para diminuir o açúcar no sangue em um sujeito, método para tratar diabetes tipo 1 em um sujeito e proteína terapêutica
Siram et al. Weight management in type 2 diabetes mellitus
Bays Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies
WO2006042002A3 (en) Compositions and methods for treating disease
Gadsby New treatments for type 2 diabetes—The DPP4 inhibitors
Rothkopf et al. Metabolic Medicine and Surgery
Kato et al. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in type 1 and type 2 diabetic patients on basal-bolus regimen

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.